Notice of Allowance - patent protection US

Biomedical Bonding AB has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO). The unique formulation enables strong adhesion between substrates and the primer is an important part of BMB’s Bonevolent™ technology that allows surgeons to do on-site customizable bone fracture fixations.

“This patent will broaden our IP protection in key geographical areas. It is an important strategic step for us when introducing our appreciated novel Bonevolent™ technology to the US market”, comments Evelina Mikaelson, CEO, Biomedical Bonding AB.

For more information, please contact:
Evelina Mikaelson, CEO
Phone: +46 (0)76 34 22 824
E-mail: evelina.mikaelson@biomedicalbonding.com
Homepage: www.biomedicalbonding.com

Biomedical Bonding AB is a platform based Swedish MedTech company that develops cutting-edge medical adhesive fixators and novel surgical methodologies with focus on the ever-growing market of hard tissue restorations. The technological platform, Bonevolent™, is market disruptive and stands for a paradigm shift in personalized surgical interventions. BMB´s vision is to become the dominant global provider of unique adhesive products suited for fracture fixation and dental restoration market. BMB´s Bonevolent™ products are easy-to-use by clinicians, will increase patient safety, save costs and resources for health care and society as a whole. BMB is a privately held company headquartered in Stockholm, Sweden.